ArticleERJ open research2026
Improving asthma control assessment and outcomes in children with asthma using an artificial intelligence digital tool: a prospective multicentre cohort study.
Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Achieving good asthma control is a goal of asthma management. In children, asthma control and quality-of-life assessments include determining the presence of wheeze. However, wheeze is unreliably reported with high disagreement (>50%) between parental and physician detection of wheeze. Objectively defining wheeze using WheezeScan™ (a user-friendly, artificial intelligence-based device) could improve assessment of asthma control and hence management. Objective: Our primary aim is to determine whether adding WheezeScan™ to routine clinical care improves parental asthma control assessment (ACA) in children (aged 4-11 years). Our secondary aims are to examine the impact of WheezeScan™ upon patient-reported outcomes (PROs), the parent asthma management self-efficacy scale (PAMS), healthcare costs and ease of WheezeScan™ use. The primary hypothesis is that using WheezeScan™ alters the ACA group. Methods: Our multicentre prospective cohort study involves 125 children with specialist-confirmed asthma. Over 5 weeks, parents/caregivers use the WheezeScan™ twice-daily at home and whenever wheezing is suspected. After the first week of using the WheezeScan™, asthma medications may be adjusted based upon the child's asthma control score and WheezeScan™ data. Study outcomes are collected at baseline, week 1 and week 5. Our primary end-point is the proportion of children whose assessment of asthma control changed between week 1 and baseline, based upon parental assessments using WheezeScan™ data. Secondary outcomes are PROs (asthma-related quality of life), PAMS, healthcare costs and WheezeScan™ ease of use. Conclusions: This protocol describes our study to determine whether using digital technology to accurately identify wheeze in children with asthma improves their asthma assessment and asthma-related PROs, including PAMS and healthcare costs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.